Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 26Gastrointestinal 5Thoracic 3CNS 3Breast 3Other hematologic neoplasm 2Lymphoid 2Gynecologic 2Genitourinary 2Other solid neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Neuroendocrine 5Neuroendocrine Tumors 2Neoplasms 2Lung Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Ovarian Epithelial 2Vipoma 1Stomach Neoplasms 1Somatostatinoma 1Small Cell Lung Carcinoma 1Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Mesothelioma 1Insulinoma 1Glucagonoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Gastrinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Fluorodeoxyglucose F18 3Doxorubicin 3Cyclophosphamide 3surufatinib 2fludarabine 2entrectinib 2Radiotherapy 2Nivolumab 2Ifosfamide 2Filgrastim 2Drug Therapy 2Cisplatin 2tivozanib 1tislelizumab 1tipifarnib 1selpercatinib 1romidepsin 1repotrectinib 1regorafenib 1pembrolizumab 1milademetan 1ganitumab 1fludarabine phosphate 1entinostat 1dostarlimab 1conatumumab 1cixutumumab 1cabozantinib 1atezolizumab 1alectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Irinotecan × Endocrine × Clear all
NCT02611024 2025-07-09

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

PharmaMar

Phase 1/2 Completed
316 enrolled
CNSEndocrineGastrointestinalGynecologicNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Ovarian Epithelial, Glioblastoma, Mesothelioma, Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡